IDO1 and IDO2 gene expression analysis by quantitative polymerase chain reaction

Tissue Antigens

Volumn 77, Issue 2, 2011, Pages 136-142

  Maiwald, S ^a   Wehner, R ^b   Schmitz, M ^b,e   Bornhauser M ^a,e   Loeb, S ^d   Wassmuth, R ^a,c,e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c DKMS Life Science Lab   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Dendritic cells; Gene expression; Indoleamine 2,3 dioxygenase; Mesenchymal stromal cells; Monocytes; Quantitative polymerase chain reaction

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE LIKE PROTEIN 1; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; GENE; GENE EXPRESSION; HUMAN; IDO1 GENE; IDO2 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STROMA CELL; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIVIRAL AGENTS; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MESODERM; MICE; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; STROMAL CELLS; T-LYMPHOCYTES;

MUS;

EID: 78650937838     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2010.01585.x     Document Type: Article

References (45)

1. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest energy of activated T cells. Blood 2005: 105: 2821-7.
2. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004: 4: 762-74.
3. Ball HJ, Sanchez-Perez A, Weiser S et al. Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice. Gene 2007: 396: 203-13.
4. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005: 105: 1815-22.
5. Kang JW, Kang KS, Koo HC, Park JR, Choi EW, Park YH. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Stem Cells Dev 2008: 17: 681-93.
6. Le Blanc BK. Mesenchymal stromal cells: Tissue repair and immune modulation. Cytotherapy 2006: 8: 559-61.
7. Le Blanc BK, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005: 7: 36-45.
8. Le Blanc BK, Rasmusson I, Gotherstrom C et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin- activated lymphocytes. Scand J Immunol 2004: 60: 307-15.
9. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006: 81: 1390-7.
10. Steckel NK, Kuhn U, Beelen DW, Elmaagacli AH. Indoleamine 2, 3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance? Scand J Immunol 2003: 57: 185-91.
11. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002: 99: 3838-43.
12. Klyushnenkova E, Mosca JD, Zernetkina V et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005: 12: 47-57.
13. Yang SH, Park MJ, Yoon IH et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 2009: 41: 315-24.
14. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006: 108: 2114-20.
15. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005: 19: 1597-604.
16. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005: 106: 4057-65.
17. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003: 75: 389-97.
18. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004: 103: 4619-21.
19. Krampera M, Pasini A, Pizzolo G, Cosmi L, Romagnani S, Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 2006: 6: 435-41.
20. Sato K, Ozaki K, Oh I et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007: 109: 228-34.
21. Steckel NK, Koldehoff M, Beelen DW, Elmaagacli AH. Indoleamine 2, 3-dioxygenase expression in monocytes of healthy nonpregnant women after induction with human choriongonadotropine. Scand J Immunol 2005: 61: 213-4.
22. Opitz CA, Litzenburger UM, Lutz C et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009: 27: 909-19.
23. Steinman RM, Inaba K, Turley S, Pierre P, Mellman I. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol 1999: 60: 562-7.
24. Loeb S, Königsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008: 111: 2152-4.
25. Suzuki T, Higgins PJ, Crawford DR. Control selection for RNA quantitation. Biotechniques 2000: 29: 332-7.
26. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001: 29: e45.
27. Kudo Y, Hara T, Katsuki T et al. Mechanisms regulating the expression of indoleamine 2, 3-dioxygenase during decidualization of human endometrium. Hum Reprod 2004: 19: 1222-30.
28. Reich NC. STAT dynamics. Cytokine Growth Factor Rev 2007: 18: 511-8.
29. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2, 3-dioxygenase gene. J Biol Chem 1996: 271: 17247-52.
30. Yuan W, Collado-Hidalgo A, Yufit T, Taylor M, Varga J. Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2, 3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell Physiol 1998: 177: 174-86.
31. Tolstrup AB, Bejder A, Fleckner J, Justesen J. Transcriptional regulation of the interferon-gamma-inducible tryptophanyl- tRNA synthetase includes alternative splicing. J Biol Chem 1995: 270: 397-403.
32. Murray MF. Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect Dis 2003: 3: 644-52.
33. Fierro F, Illmer T, Jing D et al. Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 2007: 40: 355-66.
34. King NJ, Thomas SR. Molecules in focus: indoleamine 2, 3-dioxygenase. Int J Biochem Cell Biol 2007: 39: 2167-72.
35. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003: 100: 8407-11.
36. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005: 289: F31-42.
37. Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005: 106: 1755-61.
38. Le Blanc BK, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008: 371: 1579-86.
39. Samuelsson H, Ringden O, Lonnies H, Le Blanc BK. Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 2009: 11: 129-36.
40. Sallusto FF, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994: 179: 1109-18.
41. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007: 67: 7082-7.
42. Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH. Indoleamine 2, 3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 2009: 41: 467-71.
43. Le Blanc BK, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003: 57: 11-20.
44. Steckel NK, Kuhn U, Beelen DW, Elmaagacli AH. Indoleamine 2, 3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance? Scand J Immunol 2003: 57: 185-91.
45. Jasperson LK, Bucher C, Panoskaltsis-Mortari A et al. Indoleamine 2, 3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood 2008: 111: 3257-65.